Scotch Plains, NJ, United States of America

Huifeng Niu


 

 

Average Co-Inventor Count = 11.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Huifeng Niu: Innovator in Bispecific Antibodies

Introduction

Huifeng Niu is a notable inventor based in Scotch Plains, NJ (US), recognized for his contributions to the field of biopharmaceuticals. He holds three patents that focus on bispecific antibodies, which are crucial in targeted cancer therapies. His work has significantly advanced the understanding and application of these innovative therapeutic agents.

Latest Patents

Huifeng Niu's latest patents include groundbreaking inventions related to antibodies specific for DR5. One of his patents describes bispecific antibodies that comprise at least one antigen binding site specific for DR5 and another for FAP. This invention outlines methods for their production, pharmaceutical compositions containing these antibodies, and their various uses. Another patent similarly focuses on bispecific antibodies specific for FAP and DR5, emphasizing the importance of these antibodies in therapeutic applications.

Career Highlights

Throughout his career, Huifeng Niu has worked with prominent companies in the pharmaceutical industry, including Roche Glycart AG and Hoffmann-La Roche Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in antibody technology.

Collaborations

Some of Huifeng Niu's notable coworkers include Peter Bruenker and Sherif Daouti. Their collaborative efforts have further enhanced the research and development of innovative therapeutic solutions.

Conclusion

Huifeng Niu's work in bispecific antibodies represents a significant advancement in the field of biopharmaceuticals. His patents and collaborations reflect his commitment to innovation and the development of effective cancer therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…